Poor
Not Aligned
Patient Risk:
Moderate
Summary
The AI response makes multiple specific claims about sodium disturbances not being typical/causally linked to atorvastatin. The provided label excerpts do not contain any statements about sodium balance, hyponatremia/hypernatremia, or electrolyte effects; only rhabdomyolysis/myopathy and liver enzyme abnormalities being discussed elsewhere are shown. These specific sodium-related claims are therefore unsupported by the supplied prescribing information.
Category Scores
Accurate Statements
Adverse effects most commonly associated with statins involve muscle-related effects (for example, myopathy/rhabdomyolysis) and liver enzyme elevations, rather than sodium imbalance.
The label excerpt states that serious adverse reactions discussed in other sections include rhabdomyolysis and myopathy (5.1) and liver enzyme abnormalities (5.2).
Unsupported Statements
Atorvastatin (Lipitor) is not known for causing clinically significant changes in blood sodium (hyponatremia or hypernatremia).
The provided excerpts contain no statements about sodium, hyponatremia, hypernatremia, or electrolyte disturbances.
Sodium disturbances are not a typical, expected effect listed for statins.
The provided excerpts do not list typical/expected effects for statins or include sodium disturbance information.
Sodium disturbances are not commonly reported as a primary safety issue for atorvastatin.
The provided excerpts do not discuss sodium disturbances or reporting frequency.
When electrolyte problems occur with statins, they are usually tied to other factors such as underlying illness, dehydration, kidney issues, or other medications, not atorvastatin alone.
No electrolyte causality, dehydration/kidney linkage, or discussion of other medications causing sodium issues is present in the provided excerpts.
Atorvastatin itself generally does not directly change sodium handling.
No mechanistic or sodium-handling statements are present in the provided excerpts.
Indirect effects on sodium are possible only if a person has conditions or uses drugs that make sodium balance fragile.
No conditionality or sodium-balance fragility discussion is present in the provided excerpts.
If an illness leads to dehydration or kidney stress while a patient is on multiple medications, sodium can drift.
No statements about sodium drift during illness/dehydration/kidney stress in patients taking atorvastatin are present in the provided excerpts.
Contradictions
Important Omissions
Any on-label information related to sodium disturbances (e.g., whether hyponatremia/hypernatremia is listed among adverse reactions, warnings, or precautions).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response asserts multiple sodium-related safety/causality claims that are unsupported by the provided label excerpts. Although no direct contraindication or dosing harm is stated, unsupported reassurance about sodium effects could misrepresent label-supported safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple specific claims about sodium/serum electrolyte effects and causality are not supported by the supplied prescribing information excerpts.
Suggested Improvement
Limit statements to what is present in the provided label text (e.g., that rhabdomyolysis/myopathy and liver enzyme abnormalities are discussed in Warnings and Precautions sections 5.1 and 5.2). Avoid conclusions about hyponatremia/hypernatremia or sodium handling unless supported by the provided label content.